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Abstract: Unsatisfactory compliance in the treatment of high blood pressure is frequently due 
to sequential barriers, such as insufficient patient education about the illness and low motivation 
to receive any treatment, existence of a large gap between physicians’ perceptions of the problem 
and clinical reality, complexity of the treatment potentially generating adverse effects, and a 
health care environment with few public education campaigns and incentives for better coordi-
nated supportive care. In order to improve drug compliance, establishment of personalized plans 
adapted to each patient is required. First, a good doctor–patient relationship is mandatory, with 
regular education of the patient about hypertension and its risks, discussion about adverse drug 
effects, and the complexity and cost of treatment. Second, to have any chance of success, the 
provider should offer convenient appointments and tailor the treatment regimen to the patient’s 
lifestyle and needs, with written instructions. Third, there is a need to promote active patient 
collaboration with treatment. An innovative combination of home self-measurement of blood 
pressure, use of new technology options, eg, texting or telemedicine, and creation of a multi-
disciplinary working team can offer new, effective opportunities. This approach could reduce 
cardiovascular complications by improving the control of high blood pressure, and thereby the 
overall costs of hypertension to the health care system.
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Introduction
High blood pressure is a major cardiovascular risk factor that affects approximately 
25% of the adult population in industrialized countries. It is well known that  effective 
control of hypertension markedly reduces the risk of cardiovascular events.1,2 In spite 
of this, in the US around 30% of patients treated with antihypertensive drugs do 
not achieve their target blood pressure.3 Poorly controlled hypertension confers 
a high risk of stroke, myocardial infarction, heart failure, and end-stage kidney 
 disease. Nonadherence to antihypertensive therapy is believed to be a major cause of 
unsatisfactory blood  pressure control. In a large cohort study of 10,447 patients with 
coronary artery disease, medication nonadherence was associated with uncontrolled 
blood pressure despite intensification of antihypertensive treatment, whereas high 
blood pressure became controlled over time in adherent patients.4
Medication-taking behaviors can be divided into two main concepts, namely 
adherence and persistence.5–7 Adherence is defined as appropriate use of therapy, 
including taking medications at the prescribed frequency, interval, and dosage. 
 Adherence is reported as the percentage of prescribed doses taken per defined 
period of time, and may change over time. Persistence is defined as continuing the 





use of medications for the specified treatment period and 
is measured in terms of time. Not surprisingly, these two 
medication-taking behaviors are related, ie, the lower the 
adherence, the higher the likelihood of early treatment 
discontinuation.8 The patient could also present with both 
patterns, ie, perfect adherence but nonpersistence with drug 
treatment or good persistence but bad execution (eg, drug 
holidays). Intentional and unintentional patterns of nonad-
herence have been recognized.7,9 Intentional nonadherence 
is an active process whereby the patient chooses to deviate 
from the treatment regimen. Unintentional nonadherence 
is a passive process whereby the patient may be careless or 
forgetful about adhering to the treatment regimen.7,9
Measurement of medication 
adherence
Methods for evaluation of adherence can be categorized as either 
direct or indirect.7,10 Neither of these  methods is  completely 
satisfactory. Direct methods include measurement of plasma 
drug concentrations. Plasma drug levels may be difficult to 
interpret, depending on the time interval between drug intake 
and when the blood sample is taken, drug pharmacokinetics, 
and interindividual differences in absorption and metabolism. 
Additionally, many patients typically increase their adherence 
in the few days before a scheduled visit to the clinic or labora-
tory. Finally, such tests are costly, so plasma drug levels are 
not usually measured in clinical practice.
Indirect methods are the most common approach used to 
measure treatment adherence. They include patient interview, 
questionnaire or diary, pill count, prescription refill, and 
electronic monitoring of medication use. Subjective evalu-
ation by physicians tends to overestimate adherence and to 
detect poor adherence incorrectly. Responses to six-item or 
eight-item self-administered questionnaires have been shown 
to be reliable and closely associated with blood pressure 
control.11,12 Such self-reported measurement of medication-
taking can be a simple and inexpensive tool for detecting 
low adherence.
Counting pills allows calculation of the percentage of 
prescribed doses that have been taken between two visits. Pill 
counting can overestimate adherence because the patient may 
have discarded some tablets. In addition, the pattern of missed 
doses is not identified using this approach. Based on analysis 
of prescription refills derived from pharmacy data, the medi-
cation possession ratio and the proportion of days covered 
can be obtained, both methods relating the number of doses 
dispensed to the dispensing period.7 For example, if a 30-day 
supply dispensed on day 0 is used through day 40, when the 
next 30-day supply is dispensed the medication  possession 
ratio is 30/40, ie, 75%. In the literature, the medication 
 possession ratio is often used as a dichotomous variable, with 
values $80% usually (and arbitrarily)  considered as “good” 
adherence.13 However, the patient must use a pharmacy 
 connected to the database. Electronic medication monitors 
are pill boxes equipped with a microprocessor which records 
the date and time of each opening of the container, hence 
providing accurate and detailed information on adherence. 
However, this method is expensive and generally restricted 
to clinical research.6
Quantification of medication-taking 
behavior in hypertension
Wide ranges of adherence rates in hypertension have been 
reported. The drug holiday phenomenon, ie, omission of 
medication on several sequential days, is frequent. Of more 
than 80,000 elderly Medicare beneficiaries ($65 years) 
with hypertension, 87% were adherent to at least one 
antihypertensive drug and 72% were adherent to their full 
regimen.14 Adherence was defined as proportion of days 
covered $80% and measured using automated pharmacy 
data.14 An Italian study including 18,806 newly diagnosed 
hypertensive patients showed that, although the adherence 
level varied with time, 8%, 41%, and 51% of the patients 
were classified as high (adherence .80%),  intermediate 
 (adherence 40%–79%), and low (adherence ,40%) adherers, 
respectively, at the beginning of the study.15 Such  variable 
rates may be due to the various methods used to assess 
adherence, to differences in the populations studied, to the 
antihypertensive agents used, and because adherence changes 
over time. Persistence is also reported variably. Typically, 
about 50% of patients discontinue their antihypertensive 
therapy after 1 year.5,8 At 10 years, a persistence rate of 39% 
has been reported.16
Factors related to medication-
taking behavior in hypertension
Adherence is a dynamic process. It is higher in the days 
 following a visit to the physician and in the days preceding the 
next visit, displaying a U-shaped curve referred to as “white 
coat adherence”. Numerous barriers contribute to lack of 
adherence/persistence with antihypertensive medication (see 
Table 1).5,6,10 Insufficient interaction between the patient and 
the physician may result in poor awareness on the part of the 
patient of the complications of hypertension and the benefits 
of its treatment. Adherence and persistence are typically low 
in the treatment of asymptomatic chronic diseases with drugs 
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that are costly and potentially have adverse effects. Adherence 
decreases proportionately to frequency of dose and therapeutic 
complexity.10,17 Several reports have shown that adherence and 
persistence rates are higher with renin-angiotensin blockers 
and lower with diuretics.5,6 A large study evaluated persistence 
in 242,882 newly treated patients receiving monotherapy. 
After 1 year, the proportion of patients still taking the initially 
prescribed medication was 52% for angiotensin II receptor 
blockers, 48% for angiotensin-converting enzyme inhibitors, 
40% for beta-blockers, 38% for calcium antagonists, and 30% 
for diuretics.18 Compared with patients receiving diuretics, 
those treated with other antihypertensive agents were sig-
nificantly less likely to discontinue therapy.18 A recent meta-
analysis confirms highest adherence to angiotensin II receptor 
blockers and angiotensin-converting enzyme inhibitors, and 
lowest adherence to diuretics and beta-blockers.19 In a study 
of 588 hypertensive patients, intentional nonadherence was 
reported by 9% of the participants, compared with 31% who 
reported unintentional nonadherence.9 Intentional nonadher-
ence was more likely to be reported by nonwhite patients, 
patients without diabetes, and patients who reported at least 
five adverse effects they attributed to their antihypertensive 
medication.9 Socioeconomic factors, such as lack of insur-
ance coverage, have also been related to adherence and blood 
pressure control.20,21
Consequences of poor adherence
Numerous studies indicate that low adherence to antihy-
pertensive drugs affects blood pressure control, rate of 
complications, and overall health care resource utilization 
and costs.4–6,10,14 Few large studies have related adherence to 
antihypertensive medication with hard endpoints. In the study 
of 18,806 newly diagnosed hypertensive patients discussed 
earlier, high adherers (adherence . 80%) had a significantly 
lower risk of cardiovascular events in comparison with low 
adherers (adherence , 40%) after an average follow-up 
duration of 4.6 years.15 A Canadian study reported a 22% 
reduction in stroke incidence in patients with high adherence 
(medication possession ratio $80%) compared with patients 
with lower adherence in a cohort of 83,267 newly treated 
hypertensive patients.22 More recently, an Italian population-
based prospective cohort study of 242,594 patients showed a 
significant increase in the incidence in coronary and cerebro-
vascular events in patients who discontinued treatment and 
in patients with low drug coverage, after a mean follow-up 
of 6 years.23
The impact of adherence on blood pressure control has 
been challenged.24 Some concern has been raised that the 
association between low medication adherence and adverse 
outcomes may be, at least in part, related to a “healthy 
adherer” effect. The healthy adherer effect implies that the 
lower risk of adverse outcomes associated with adherence 
may be a  surrogate marker for overall healthy behavior.25 
For example, data from the Candesartan in Heart Failure 
Assessment of Reduction in Mortality and Morbidity 
(CHARM) study in patients with congestive heart failure 
showed that patients with a high rate of adherence to placebo 
had better outcomes, including mortality, compared with 
patients with low adherence to the active treatment.26 It is 
hypothesized that patients who take their medication regularly 
are also more likely to perform other healthy behaviors, such 
as eating properly and exercising regularly.7 Hence, there is 
widespread agreement to promote healthy lifestyle habits 
as well as to overcome barriers to good medication-taking 
behavior in the hope of reducing the burden of cardiovascular 
disease.1
Improving adherence  
to antihypertensive medication
As mentioned earlier, poor medication adherence is an 
enormous public health problem. Whatever the patient’s age, 
gender, race, or comorbidities, lowering blood pressure will 
be beneficial at every stage of the cardiovascular continuum, 
and the target should be ,140/90 mmHg in all adult patients 
younger than 80 years. Initiating drug treatment is useless if 
the tablets are unused, and identification of this as a potential 
problem is crucial. A combinational approach is often needed 
to increase the compliance rate.
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No immediate consequences of stopping therapy
Therapy Adverse effects 
Complexity of regimen
Socioeconomic Cost of medication 
Unemployment/poverty 
Lack of insurance 
Lack of transportation 
Social deprivation
Health system inadequate health care coverage 
Difficult access to health care 
Lack of continuity of care





There are three important steps to improve drug 
adherence. We have to prevent noncompliance, to detect it, 
and to improve and/or maintain vigilance. However, there are 
sequential barriers to drug adherence in hypertension, ie, poor 
communication, low motivation, complexity of treatment, 
acute side effects (influence on adherence) but also delayed 
side effects, limited long-term motivation, and reinforcement 
of poor habits (influence on persistence).
In the first place, to detect noncompliance, there is a need 
to talk about its possible existence (increase awareness of 
the problem) and to monitor treatment whenever possible. 
 Several recommendations can be made to improve this 
problem when identified. There are at least four important 
determining influences on compliance which should be 
 recognized and brought under control:
•	 The patient (hypertension is seen as an unavoidable 
consequence of old age or of anxiety, an asymptomatic 
disorder, and therefore perceived as benign)
•	 The health provider (not aware of and not trained to test 
for the problem)
•	 The treatment (drug price, undesirable adverse effects)
•	 The therapeutic environment (complexity of the 
regimen).
Gallup and Cotugno27 showed that treatment for high blood 
pressure was stopped by patients because of side effects in 11% 
of cases, thinking that the doctors asked them to do this in 25%, 
believing themselves to be cured (because they were without 
symptoms) in 46%, and for financial reasons in 6%.
Consistent control of blood pressure requires that patients 
with high blood pressure follow dietary regimens and drug 
treatment. Dietary changes, especially reduction of salt 
and excess weight, are crucial in the management of the 
 hypertensive population. This approach can decrease the need 
for antihypertensive treatment. This is important because 
antihypertensive therapy may have potential side effects, 
whereas high blood pressure is very often  asymptomatic. 
Therefore, limiting the number of agents needed to  control 
blood pressure by dietary and lifestyle measures is an 
interesting approach. However, lifestyle advice is  generally 
not followed in the long term, except if the patient is 
 motivated. Compliance with dietary therapy is better, and 
success rates in achieving blood pressure control are higher 
when accompanied by active patient guidance or counseling 
by clinicians and ancillary medical personnel with expertise 
in dietary management. Less than one-third of treated patients 
change their dietary habits or increase their physical activity, 
and in this situation, persistence with the drug treatment is 
likely to be suboptimal.
To achieve better compliance, we need to improve the 
relationship between the patient and the health care provider 
and to integrate this into the health care system. Patients need 
to know the risks associated with their hypertension and to 
consider them as serious, to believe in the efficacy of their 
treatment, to be motivated by well defined goals, and to know 
the effects expected from therapy.
In addition to improvement of the health care system with 
guidelines to increase adherence, the creation of a medical 
treatment team, supporting public education  campaigns 
and incentives for better coordinated support care, patient/ 
provider education, and engagement should be better 
 developed. An approach to improve compliance must draw 
on aspects of educational, behavioral, affective, and provider 
intervention strategies.
The patient
Educating and involving patients is crucial to  motivating 
them and making them aware of the necessity for 
 treatment. Each patient is an individual, and the goal of 
 patient-centered approaches to improve compliance with 
antihypertensive therapy is to identify each patient’s barriers 
to  compliance and develop personalized self-management 
plans.  Adherence could be enhanced further still when the 
patient is empowered to become involved in medical deci-
sions and monitoring their care. There is a diverse range 
of patient- related factors that can affect compliance with 
antihypertensive therapy. The importance of any particular 
factor will differ between individuals and also in the same 
individual over time. The asymptomatic nature of hyper-
tension is  particularly important, because this is likely to 
influence the perceived importance of other patient-related 
factors.
An important point cited by the European Society of 
Hypertension guidelines in 2007 is the crucial role of patient 
information on the risk of hypertension and the benefits of 
treating it. Patient understanding of the long-term health 
implications and the asymptomatic nature of uncontrolled 
hypertension is likely to improve compliance with antihyper-
tensive therapy. Patient education can be achieved in many 
ways, including verbal, written, and visual approaches, or 
a combination of these approaches. Whichever approach is 
utilized, the language used should be clear and free of jargon. 
Instructions should be simple and unambiguous.
The health care provider
The role of the health care provider is particularly important 
in the field of drug compliance. First, the health care provider 
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must propose tight follow-up with frequent office visits. 
Office visits provide an important opportunity to reinforce 
hypertension-related educational messages. Clinicians 
could do more to underscore the importance of medication 
adherence and healthy living to their hypertensive patients. 
Moreover, the health care provider must be trained in the 
problem of nonadherence.
Good communication and interpersonal skills and 
regular appointments are examples of health care provider 
interventions that can foster a collaborative relationship 
with patients and improve patient compliance with 
antihypertensive therapy. Provider interventions for 
improving compliance are ultimately intended to achieve 
a collaborative and interactive partnership between health 
care provider and patient, whereby they work together 
to control blood pressure. However, there is a large gap 
between physicians’ perceptions and clinical reality when 
it comes to assessing the success of therapy, which is often 
overestimated. Physicians are of course fully aware that 
compliance in hypertension often tails off substantially within 
the first year of treatment.
The health care provider must be very attentive to identify 
problems which could interfere with adherence. Some 
depressive conditions could exist, leading to, for example, 
missed medical appointments. It is thus important to identify 
and contact patients who are not showing up to consultations 
and to focus on patients in whom therapeutic goals are not 
reached. Convenient appointments need to be given, the 
treatment regimen should be tailored to the patient’s lifestyle 
and needs, simplified or adapted if necessary, individualized 
written instructions should be provided, and the patient 
given encouragement to collaborate in their treatment 
(see Table 2).
The treatment
Simplification of the treatment regimen is important. A once-
daily dosing regimen is useful. Eisen et al28 showed that 
compliance decreased from 84% for a single daily dose to 
59% for a three times daily dosage. Because monotherapy 
is usually insufficient to control blood pressure, physicians 
are increasingly using two or more antihypertensive agents 
concurrently. When this is the case, fixed-dose combinations 
deliver agents from different therapeutic classes to provide 
effective blood pressure reduction. The medications are pack-
aged in a convenient format for use in a simple treatment 
regimen. This can help to overcome the adherence issue.29 
Minimizing the total number of daily doses has been found to 
be more important in promoting adherence, and perhaps more 
importantly persistence with treatment, than minimizing 
the total number of medications.30 Yet this approach seems 
not always sufficient. For instance, a longitudinal database 
study of 4783 patients prescribed once-daily antihypertensive 
treatment in 1989–2006 reported that half had stopped taking 
their prescribed treatments within 1 year.8
Side effects must also be monitored. Great attention must 
be paid at each medical contact to acknowledge drug side 
effects (even subtle) and one must be prepared to change 
drug doses or types of drug if needed. Tolerability is one 
of the main factors determining adherence, because it has a 
major impact on the probability of treatment discontinuation. 
The angiotensin receptor blockers (and probably also the 
new renin inhibitors) are the safest and best tolerated class 
of antihypertensive drugs, and therefore their use increases 
the chance that a patient will persist with antihypertensive 
treatment over time. In a retrospective cohort study of a 
large patient population (n = 21,723), Bloom31 showed 
that angiotensin receptor blockers had the highest rate of 
persistence (64%) at 1 year. This was confirmed at 4 years 
(51%) by a longitudinal analysis of a subset of this study 
cohort (n = 15,175). Persistence with angiotensin receptor 
blockers was significantly greater than when using other 
classes of antihypertensives.32
Another way to improve blood pressure control, without 
dealing directly with compliance, is to use more “forgiv-
ing” antihypertensive agents with longer half-lives, which 
will probably help to maintain a more stable blood pressure, 
despite imperfect adherence. The physician should choose the 
agent with the longest half-life in each class. These forgiving 
drugs should have efficacy which is unaffected by delayed 
or missed doses. However, thiazide diuretics, although less 
widely used due to potential side effects, are among the 
most powerful in this respect. Moreover, such treatment 
Table 2 Ten guidelines for the physician to improve antihypertensive 
drug compliance
 1.  educate the patient about hypertension and its treatment with clear 
and accepted goals
 2. Be easily available to communicate regularly with the patient
 3.  Keep the treatment as simple and cheap as possible with written 
information
 4. Prescribe considering the patient and potential drug interactions
 5. Avoid adverse drug effects by starting the treatment at a low dose
 6.  Stop any inefficient or badly tolerated treatment and avoid 
therapeutic inertia
 7. Combine efficient and well tolerated drugs in the same pill
 8. Stimulate the patient to be active in medical management
 9.  Create a multidisciplinary team to improve family and community 
support
10. Use all possible modern reminder aids to ensure daily drug intake





is cheap. Thiazide diuretics should also be  considered when 
prescribing a drug. In chronic disease, when drug treatment is 
proposed for a long period of time, it is very important to con-
sider compliance in the evaluation of the cost of medication. 
Expensive medications are one of the  treatment characteris-
tics which reduce adherence, and probably  persistence with 
therapy even more.
Another approach in antihypertensive prescribing 
could be initiation of low-dose combination therapy, as 
proposed by a Canadian group.33 They suggest starting 
initial antihypertensive therapy with a low-dose angiotensin-
converting enzyme inhibitor-diuretic combination or an 
angiotensin receptor blocker-diuretic combination. The 
 combination therapy can then be uptitrated to the highest 
dose, if necessary. This simplified antihypertensive algo-
rithm using such initial low-dose, fixed-dose combination 
therapy could be superior to guideline-based practice for the 
management of hypertension.
The therapeutic environment
Education of the patient and the health care provider will never 
be enough to solve the problem of nonadherence.34 Patients 
have many reasons for missing their treatment but they do 
not always share these with their physician. Discussing these 
reasons takes time, but someone must explore the patient’s 
beliefs about antihypertensive medication and persuade 
them that the benefits outweigh any worries they may have. 
One reason could be that, in most health care systems, 
physicians are not given enough incentives or resources to 
control blood pressure effectively. This is indeed a time-
intensive intervention. A recent paper35 indicates that “pay for 
performance” has no effect on hypertension-related clinical 
outcomes. Quality of care in the UK was not modified by 
introducing such financial measures. However, our task as 
health care providers is to promote awareness of the dangers 
of hypertension across government, the public, health 
professionals, carers, and perhaps even schoolchildren, who 
will be the next generation of hypertensive people if no action 
is taken. Because hypertension is a chronic disease, it is also 
important to maintain and even improve drug adherence by 
supervising treatment and positively reinforcing compliance, 
perhaps involving a family member. The goal of behavioral 
approaches is to modify compliance by targeting, shaping, 
and reinforcing behavior patterns that improve compliance 
with antihypertensive therapy. Behavioral approaches can be 
implemented by means of simplifying treatment schedules, 
using reminder techniques, modifying drug packaging, and 
encouraging self-monitoring of blood pressure by patients.
Affective intervention approaches are useful to improve 
compliance with antihypertensive therapy. These approaches 
focus on feelings and emotions, and often rely on family 
relationships and social networks. Affective interventions 
can be implemented by means of social support networks, 
involvement and education of family members, counseling, 
home visits, and nurse telephone calls. Creation of efficient 
medical teams should be encouraged. Patients may respond 
more positively to various aspects of a message depending 
on the messenger. Nurses, for instance, can spend more time 
with patients and reiterate the message in alternative ways. 
They can also reinforce drug compliance by using the short 
message service. Text messages could hold potential for 
improving adherence to some drug regimens. This kind of 
intervention has been shown to be useful in improving drug 
compliance in patients suffering from chronic infectious 
 diseases, such as tuberculosis.36 The pharmacist can undertake 
regular medication reviews, do blood pressure monitoring, 
educate the patient on avoidance of some side effects and on 
improving drug efficacy, by giving advice on how and when 
the drug should be taken, and could alert the physician when 
repeat prescriptions appear ineffective or are not collected 
by the patient. This “multidisciplinary team” could be very 
effective in improving blood pressure control.37 Patients in 
whom hypertension is managed by a physician–pharmacist 
team have lower blood pressure levels, and are more likely 
to reach their target blood pressure than patients treated by 
a physician alone.38
Patients should be active participants in their own 
treatment. This needs therapeutic education enabling 
hypertensive patients to manage their illness with the help of 
health partners. For example, patients should be encouraged to 
monitor their own blood pressure regularly at home. Edmonds 
et al39 monitored 37 patients with high blood pressure treated 
for 3 months. They had been taught self-measurement, and 
their compliance was 65% at the beginning of the trial and 
81% after 3 months. Of those who were noncompliant prior 
to the study, adherence was achieved in 70% of cases after 
self-measurement. This approach could also motivate patients 
to adhere to both lifestyle changes and medication. Of eleven 
randomized controlled trials, six (54%) reported a significant 
improvement in compliance attributable to self-measurement 
of blood pressure.40 In this way, control of blood pressure was 
higher,41 and the patients were more satisfied by this approach, 
which did not increase the cost of treatment.42 The success of 
such an approach is even greater if self-monitoring, Internet 
support, and pharmacy management are used together.43 
Therefore, an innovative combination of self-management, 
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using an alarm clock function on a mobile phone and 
new technology eg, short reminder message services and 
telemedicine, as well as a multidisciplinary approach offer 
new therapeutic possibilities. It has also been shown recently 
that home blood pressure telemonitoring could be helpful in 
addressing the problem of compliance.44
Conclusion
No single intervention strategy is superior for improving 
drug compliance, and complex methods are needed to 
identify individual barriers to compliance and help to develop 
personalized self-management plans. To prevent, detect, 
and improve the problem of drug adherence, we must give 
convenient appointments, simplify and adapt treatment with 
individualized instructions, and promote patient collaboration 
with treatment. We must also discuss compliance, monitor 
treatment whenever possible, identify and contact patients 
who are not attending their appointments, and focus on 
patients in whom therapeutic goals are not being reached. Our 
role as doctors is to supervise treatment, provide feedback on 
treatment to the patient, and involve family members, nurses, 
and pharmacists to reinforce compliance.
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